Sanibel Captiva Trust Company Inc. Has $3.51 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sanibel Captiva Trust Company Inc. cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,922 shares of the biopharmaceutical company’s stock after selling 25 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,506,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. International Assets Investment Management LLC increased its holdings in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. Icon Wealth Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after buying an additional 75,569 shares during the last quarter. State Street Corp boosted its position in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares during the period. Finally, Epoch Investment Partners Inc. grew its holdings in Regeneron Pharmaceuticals by 57.7% during the 2nd quarter. Epoch Investment Partners Inc. now owns 163,296 shares of the biopharmaceutical company’s stock worth $171,629,000 after acquiring an additional 59,745 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on REGN shares. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Wolfe Research started coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Evercore ISI cut their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Finally, Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $681.58 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The stock has a market capitalization of $74.90 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. The company’s 50-day moving average is $738.60 and its 200-day moving average is $949.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.